ACH-000143 is a novel and Potent Melatonin Receptor Agonist.

S-26131 (S26131) is a novel and selective MT1 and MT2 antagonist, with Ki values of 0.5 and 112 nM for MT1 and MT2, respectively.

Agomelatine L(+)-Tartaric acid is a potent antidepressant acting as a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively.

Agomelatine hydrochloride (S-20098 HCl) is a potent antidepressant acting as a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively.

Tasimelteon (formerly BMS-214778; VEC-162; trade name: Hetlioz), a novel circadian regulator, is the first medication approved by both FDA and European Medicines Agency (EMA) for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24), or sleep-wake disorder in blind individuals.